Claims
- 1. A compound of the formula: ##STR8## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.3 is selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl and --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl, thienyl, furanyl or pyridinyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy, and trifluoromethyl;
- or NR.sup.2 R.sup.3 is 1, 2, 3, 4-tetrahydroquinolin-1-yl, or 1, 2, 3, 4-tetrahydroquinolin-2-yl;
- m is 1-5;
- n is 1 or 2;
- Y is halogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy;
- or a pharmraceutcally acceptable salt thereof.
- 2. A compound according to claim 1 wherein R.sup.3 is benzyl, substituted benzyl, thienylmethyl, furanylmethyl, phenylbutyl, or cyclohexylmethyl.
- 3. A compound according to claim 1 which is 4(2-benzylamino-ethoxy)-6-chloro-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 4. A compound according to claim 1 which is 6-chloro-4-{2-[(thiophen-3-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 5. A compound according to claim 1 which is 6-Chloro-4-{2-[(thiophen-2-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 6. A compound of the formula: ##STR9## wherein: R.sup.1 is hydrogen;
- R.sup.2 is hydrogen;
- R.sup.3 is selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl and (CH.sub.2).sub.m Ar where Ar is phenyl, naphdlyl, thienyl, furanyl or pyridyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy and trifluoromethyl:
- or NR.sup.2 R.sup.3 is 1, 2, 3, 4-tetrahydroquinolin-1-yl or 1, 2, 3, 4-tetrahydro-isoquinolin-2-yl;
- m is 1-5;
- n is 1 or 2; and
- Y is hydrogen.
- 7. A compound according to claim 6 wherein R.sup.3 is benzyl, substituted benzyl, thienylmethyl, furanylmethyl, phenylbutyl, or cyclohexylmethyl.
- 8. A compound according to claim 6 which is 4-(2-benzylamino-ethoxy)-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 9. A compound according to claim 6 which is 4-[2-(4-methyl-benzyl)-amino-ethoxy]-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 10. A compound according to claim 6 which is 4-(2-benzylamino-propoxy) 1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 11. A compound according to claim 6 which is 4-{2-[(naphthalen-1-ylmethyl)-amino]-ethoxy}-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 12. A compound according to claim 6 which is 4-[2-(4-tert-butyl-benzylamino)-etboxy]-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 13. A compound according to claim 6 which is 4-[2-(4-chloro-benzylamino)-ethoxy]-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 14. A compound which is 4-[2-(3,4 Dihydro 1H-isoquinolin-2-yl)-ethoxy]-1,3-dihydro-benzoimidazole-2-thione or a pharmaceutically acceptable salt thereof.
- 15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount or a compound of the formula ##STR10## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.3 is selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl and --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl, thienyl, furanyl or pyridinyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy, and trifluoromethyl,
- or NR.sup.2 R.sup.3 is 1, 2, 3, 4-tetrahydroquinolin-1-yl, or 1, 2, 3, 4-tetrahydroisquinolin-2-yl;
- m is 1-5;
- n is 1 or 2,
- Y is halogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy; or a pharmaceutically acceptable salt thereof.
- 16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 6.
- 17. A method of treating diseases in a mammal that respond to treatment with a dopamine D.sub.2 agonist which comprises administration to a mammal in need thereof a therapeutically effective amount of a compound of the formula ##STR11## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.2 is hydrogen or C.sub.1 -C.sub.6 alkyl;
- R.sup.3 is selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl and --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl, thienyl, furanyl or pyridinyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy, and trifluoromethyl,
- or NR.sup.2 R.sup.3 is 1, 2, 3, 4-terrahydroquinolin-1-yl, or 1, 2, 3, 4-tetrahydroisoquinolin-2-yl;
- m is 1-5;
- n is 1 or 2;
- Y is halogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy;
- or a pharmaceutically acceptable salt thereof.
- 18. The method according to claim 17 wherein the disease treated is schizophrenia.
- 19. The method according to claim 17 wherein the disease treated is Tourette's syndrome.
- 20. The method according to claim 17 wherein the disease treated Parkinson's disease.
- 21. The method according to claim 17 wherein the disease treated is drug or alcohol addiction.
- 22. A method of treating diseases in a mammal that responds to treatment with a dopamine D.sub.2 agonist which comprises administration to a mammal in need thereof a therapeutically effective amount of a compound of the formula: ##STR12## wherein: R.sup.1 is hydrogen;
- R.sup.2 is hydrogen;
- R.sup.3 is selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms, cyclohexylmethyl and --(CH.sub.2).sub.m Ar where Ar is phenyl, naphthyl, thienyl, furanyl or pyridyl, each optionally substituted by one or two substituents selected independently from C.sub.1 -C.sub.6 alkyl, halogen, C.sub.1 -C.sub.6 alkoxy and trifluoromethyl;
- or NR.sup.2 R.sup.3 is 1, 2, 3, 4-tetrahydroquinolin-1-yl or 1, 2, 3, 4-tetrahydro-isoquinolin-2-yl;
- m is 1-5;
- n is 1 or 2; and
- Y is hydrogen.
- 23. The method according to claim 22 wherein the disease treated is schizophrenia.
- 24. The method according to claim 22 wherein the disease treated is Tourette's syndrome.
- 25. The method according to claim 22 wherein the disease treated Parkinson's disease.
- 26. The method according to claim 22 wherein the disease treated is drug or alcohol addiction.
Parent Case Info
This application claims benefit of priority to provisional application No. 60/038,423 filed Feb. 18, 1997.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4140789 |
Jaeggi |
Feb 1979 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0707007 |
Apr 1996 |
EPX |
WO8601204 |
Feb 1986 |
WOX |
WO9723216 |
Jul 1997 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Jaen J.C. et al., Journal of Med. Chem., vol. 31, No. 8 (Aug. 1988) p 1621-1625. |
Staehelin et al., J. Biological Chemistry 258 (6) 3496-3502, 1983. |